Nationwide Surveillance of Azole Resistance in Aspergillus Diseases
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Aspergillus disease affects a broad patient population, from patients with asthma to immunocompromised patients. Azole resistance has been increasingly reported in both clinical and environmental Aspergillus strains. The prevalence and clinical impact of azole resistance in different patient populations are currently unclear. This 1-year prospective multicenter cohort study aimed to provide detailed epidemiological data on Aspergillus resistance among patients with Aspergillus disease in Belgium. Isolates were prospectively collected in 18 hospitals (April 2011 to April 2012) for susceptibility testing. Clinical and treatment data were collected with a questionnaire. The outcome was evaluated to 1 year after a patient's inclusion. A total of 220 Aspergillus isolates from 182 patients were included. The underlying conditions included invasive aspergillosis ( n = 122 patients), allergic bronchopulmonary aspergillosis (APBA) ( n = 39 patients), chronic pulmonary aspergillosis ( n = 10 patients), Aspergillus bronchitis ( n = 7 patients), and aspergilloma ( n = 5 patients). The overall azole resistance prevalence was 5.5% (95% confidence interval [CI] 2.8 to 10.2%) and was 7.0% (4/57; 95% CI, 2.3 to 17.2%) in patients with APBA, bronchitis, aspergilloma, or chronic aspergillosis and 4.6% in patients with invasive aspergillosis (5/108; 95% CI, 1.7 to 10.7%). The 6-week survival in invasive aspergillosis was 52.5%, while susceptibility testing revealed azole resistance in only 2/58 of the deceased patients. The clinical impact of Aspergillus fumigatus resistance was limited in our patient population with Aspergillus diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917
Self-citationStevens, D. A., Moss, R. B., Kurup, V. P., Knutsen, A. P., Greenberger, P., Judson, M. A., Denning, D. W., Crameri, R., Brody, A. S., Light, M., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/376525 · Cited by 790
van der Linden, J. W. M., Camps, S. M. T., Kampinga, G. A., Arends, J. P. A., Debets-Ossenkopp, Y. J., Haas, P. J. A., Rijnders, B. J. A., Kuijper, E. J., van Tiel, F. H., Varga, J., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit320 · Cited by 342 · cited 7×
“In the latter, only a few predominant resistance mechanisms occur, namely, the CYP51A alterations TR34/ L98H and TR46/Y121F/T289A (4, 5).”
InfluentialEpidemiological trends in invasive aspergillosis in France: the SAIF network (2005–2007)
Lortholary, O., Gangneux, J.-P., Sitbon, K., Lebeau, B., de Monbrison, F., Le Strat, Y., Coignard, B., Dromer, F., & Bretagne, S. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03548.x · Cited by 331
Factors associated with mortality in transplant patients with invasive aspergillosis
Baddley, J. W., Andes, D. R., Marr, K. A., Kontoyiannis, D. P., Alexander, B. D., Kauffman, C. A., Oster, R. A., Anaissie, E. J., Walsh, T. J., Schuster, M. G., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/652768 · Cited by 303 · cited 2×
“Total IgE (median [range]) (IU/ml) 647 (126-5,000) 23 (4-67) 24 (11-180) Specific IgG (median [range]) (mg/liter) 55 (3-70) 113 (80-159) 65 (20-174)”
D'Haese, J., Theunissen, K., Vermeulen, E., Schoemans, H., De Vlieger, G., Lammertijn, L., Meersseman, P., Meersseman, W., Lagrou, K., & Maertens, J. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06423-11 · Cited by 186 · cited 3×
“Total IgE (median [range]) (IU/ml) 647 (126-5,000) 23 (4-67) 24 (11-180) Specific IgG (median [range]) (mg/liter) 55 (3-70) 113 (80-159) 65 (20-174)”
Cited by
Aspergillus fumigatus and Aspergillosis in 2019
Latgé, J.-P., & Chamilos, G. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00140-18 · Cited by 1,400
Verweij, P. E., Chowdhary, A., Melchers, W. J. G., & Meis, J. F. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ885 · Cited by 561
“Belgium 2006 C + E 2012 [12, 27] Tanzania 2013 E 2014 [32]”
BackgroundInfluentialAntifungal Susceptibility Testing: Current Approaches
Berkow, E. L., Lockhart, S. R., & Ostrosky-Zeichner, L. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00069-19 · Cited by 368
Emerging Fungal Infections: New Patients, New Patterns, and New Pathogens
Friedman, D. Z. P., & Schwartz, I. S. (2019) · Journal of Fungi · doi:10.3390/jof5030067 · Cited by 357
Paulussen, C., Hallsworth, J. E., Álvarez‐Pérez, S., Nierman, W. C., Hamill, P. G., Blain, D., Rediers, H., & Lievens, B. (2017) · Microbial Biotechnology · doi:10.1111/1751-7915.12367 · Cited by 334
Metadata
- Authors
- Vermeulen, E., Maertens, J., De Bel, A., Nulens, E., Boelens, J., Surmont, I., Mertens, A., Boel, A., & Lagrou, K.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2015-08
- Volume
- 59
- Issue
- 8
- Pages
- 4569-4576
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W1937265692
- Cited by
- 92
- References
- 6
- FWCI
- 8.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nationwide Surveillance of Azole Resistance in Aspergillus Diseases. https://app.cochat.ai/papers/10.1128/aac.00233-15
- The paper
- Vermeulen, E., Maertens, J., De Bel, A., Nulens, E., Boelens, J., Surmont, I., Mertens, A., Boel, A., & Lagrou, K. (2015). Nationwide Surveillance of Azole Resistance in Aspergillus Diseases. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00233-15
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.